The lethal interaction of PARP inhibition and BRCA-deficiency is currently exploited by FDA approved PARP inhibitors, but resistance (innate or acquired) is commonplace [315]. The gene discussed is PARP1; the disease is hyperinsulinemic hypoglycemia, familial, 4.